MX2023006546A - Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas. - Google Patents

Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.

Info

Publication number
MX2023006546A
MX2023006546A MX2023006546A MX2023006546A MX2023006546A MX 2023006546 A MX2023006546 A MX 2023006546A MX 2023006546 A MX2023006546 A MX 2023006546A MX 2023006546 A MX2023006546 A MX 2023006546A MX 2023006546 A MX2023006546 A MX 2023006546A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cell populations
selective expansion
engineered
Prior art date
Application number
MX2023006546A
Other languages
English (en)
Inventor
Yan Li
Orit Foord
Aya Jakobovits
Radhika Chetan Desai
Daulet Kadyl Satpayev
Marianne Theresa Santaguida
Yifeng Frank Jing
Andy An-Deh Lin
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of MX2023006546A publication Critical patent/MX2023006546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para la expansión selectiva de la o las poblaciones de células T gd, composiciones y mezclas de estos y métodos para utilizar los mismos como una terapia. Poblaciones de células T gd enriquecidas, no modificadas y modificadas de la descripción son útiles en el tratamiento de diversos cánceres, enfermedades infecciosas y trastornos autoinmunes.
MX2023006546A 2016-05-12 2018-11-12 Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas. MX2023006546A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662335572P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
MX2023006546A true MX2023006546A (es) 2023-06-16

Family

ID=60267413

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013864A MX2018013864A (es) 2016-05-12 2017-05-12 Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
MX2023006546A MX2023006546A (es) 2016-05-12 2018-11-12 Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018013864A MX2018013864A (es) 2016-05-12 2017-05-12 Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.

Country Status (11)

Country Link
US (2) US11299708B2 (es)
EP (1) EP3454870A4 (es)
JP (2) JP7210286B2 (es)
KR (1) KR102519861B1 (es)
CN (1) CN110072533B (es)
AU (2) AU2017261804A1 (es)
CA (1) CA3023993A1 (es)
IL (2) IL301527A (es)
MX (2) MX2018013864A (es)
WO (1) WO2017197347A1 (es)
ZA (1) ZA201808140B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831109B1 (en) 2012-03-28 2017-12-06 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
CN110494558B (zh) * 2017-02-08 2023-07-07 新加坡科技研究局 Gamma delta t细胞和增强其杀肿瘤活性的方法
JP7486953B2 (ja) * 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
EP3692058A1 (en) 2017-10-06 2020-08-12 Oslo Universitetssykehus HF Chimeric antigen receptors
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
WO2019160829A1 (en) * 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
EP3796923A4 (en) * 2018-05-18 2022-03-09 Children's National Medical Center IMPROVED TARGETED T-CELL THERAPY
US20210283180A1 (en) * 2018-07-06 2021-09-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
CN112955466A (zh) * 2018-07-20 2021-06-11 杜克大学 用于癌症治疗的抗lypd3 car t细胞疗法
CN112912494A (zh) * 2018-07-26 2021-06-04 耶稣圣婴儿童医院 γ-δT细胞和自然杀伤细胞的治疗制剂以及制造和使用方法
US20210371525A1 (en) * 2018-09-19 2021-12-02 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
CA3115059A1 (en) 2018-10-01 2020-04-09 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered .gamma..delta.-t cells for treatment of solid tumors
MX2021003745A (es) * 2018-10-01 2021-05-14 Adicet Bio Inc Composiciones y métodos relacionados con células t gamma delta modificadas y no modificadas para el tratamiento de tumores hematológicos.
GB2569692A (en) * 2018-10-30 2019-06-26 Tc Biopharm Ltd T cell antigen receptor chimera
CA3126896A1 (en) * 2018-12-03 2020-06-11 Adicet Bio Inc. Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof
CA3145523A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
US20220290101A1 (en) 2019-08-16 2022-09-15 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
AU2020398623A1 (en) * 2019-12-03 2022-06-23 Adicet Therapeutics, Inc. Methods for expanding γδ T-cell populations with multivalent agents and compositions thereof
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
UY39127A (es) * 2020-03-13 2021-09-30 Janssen Biotech Inc Materiales y métodos para modular la inmunidad mediada por cadena delta
MX2022013920A (es) * 2020-05-07 2022-11-30 Phanes Therapeutics Inc Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
CN111748519A (zh) * 2020-07-06 2020-10-09 深圳市人民医院 成纤维细胞的原代培养方法
MX2023001792A (es) * 2020-08-12 2023-03-10 Univ Central Florida Res Found Inc Metodos y composiciones para estimular los linfocitos t gamma delta.
CN116209456A (zh) 2020-08-14 2023-06-02 伽马三角洲疗法有限公司 多特异性抗TCRδ可变1抗体
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
WO2022175414A1 (en) 2021-02-17 2022-08-25 Adaptate Biotherapeutics Ltd. Multispecific anti-tcr delta variable 1 antibodies
WO2022258606A1 (en) * 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US11999968B2 (en) * 2021-10-22 2024-06-04 Fullhope Biomedical Co., Ltd Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
CA3238458A1 (en) * 2021-11-18 2023-05-25 Regents Of The University Of Minnesota Large-scale expansion of engineered human gamma delta t cells
WO2023102615A1 (en) * 2021-12-09 2023-06-15 The University Of Melbourne Modified t cell receptors and uses thereof
TW202341971A (zh) 2022-02-16 2023-11-01 法商普萊歐塞拉公司 使用car細胞及s1p受體調節劑之治療方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
WO2023250336A1 (en) * 2022-06-21 2023-12-28 Kiromic BioPharma, Inc. Methods for generating gamma delta t-cells and related compositions
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024097864A1 (en) * 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5185250A (en) 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
CA2376228A1 (en) 1999-06-17 2000-12-28 Martha K. Newell Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
US6737398B1 (en) * 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CN1306027C (zh) 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
US20060205089A1 (en) 2003-04-14 2006-09-14 Montana State University Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
MXPA06014075A (es) 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
US7340913B2 (en) 2004-08-05 2008-03-11 Manitowoc Foodservice Companies, Inc. Ice machine and ice-making assembly including a water distributor
US20080026986A1 (en) 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
SI3339445T1 (sl) 2006-09-08 2020-12-31 Abbvie Bahamas Ltd. Beljakovine za vezavo interlevkin-13
JP2012501178A (ja) 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド Ｔ細胞受容体抗体およびその使用方法
US10260062B2 (en) 2010-01-22 2019-04-16 Sangamo Therapeutics, Inc. Targeted genomic alteration
US9784738B2 (en) 2010-01-23 2017-10-10 Genefluidics, Inc. Modular cartridge for liquid transport
US8324914B2 (en) 2010-02-08 2012-12-04 Genia Technologies, Inc. Systems and methods for characterizing a molecule
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
US9074000B2 (en) 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
ES2643387T3 (es) * 2011-05-19 2017-11-22 Instituto De Medicina Molecular Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US10351824B2 (en) * 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
JP2016501013A (ja) 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
CN102994448A (zh) 2012-12-13 2013-03-27 上海柯莱逊生物技术有限公司 一种体外扩增γδT细胞的方法
JP6480874B2 (ja) 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Ｔａｌｅｎに基づく遺伝子修正
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
AU2015350103A1 (en) * 2014-11-17 2017-06-29 Adicet Bio, Inc. Engineered gamma delta T-cells
EP3307875B1 (en) * 2015-06-09 2021-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive

Also Published As

Publication number Publication date
US20220372439A1 (en) 2022-11-24
JP2022180371A (ja) 2022-12-06
WO2017197347A1 (en) 2017-11-16
AU2017261804A1 (en) 2018-11-29
CA3023993A1 (en) 2017-11-16
CN110072533A (zh) 2019-07-30
IL262919B2 (en) 2023-08-01
IL262919B1 (en) 2023-04-01
ZA201808140B (en) 2024-03-27
IL262919A (en) 2018-12-31
US11299708B2 (en) 2022-04-12
JP2019519210A (ja) 2019-07-11
EP3454870A4 (en) 2020-03-04
KR20190016960A (ko) 2019-02-19
IL301527A (en) 2023-05-01
CN110072533B (zh) 2024-04-02
JP7210286B2 (ja) 2023-01-23
MX2018013864A (es) 2019-06-10
EP3454870A1 (en) 2019-03-20
KR102519861B1 (ko) 2023-04-10
AU2023278051A1 (en) 2024-02-01
US20190119634A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
MX2023006546A (es) Metodos para la expansion selectiva de poblaciones de celulas t gama y composiciones de estas.
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
MX2019012233A (es) Anticuerpos anti-sirpa.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2022007522A (es) Anticuerpos anti-cd27.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
MX2019014974A (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
MX2017013564A (es) Formulaciones de glucopiranosil lipido a y alérgenos de cacahuete para administración sublingual.
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
MX2021006503A (es) Métodos para la expansión in vivo selectiva de poblaciones de células t gamma delta y composiciones de estas.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018007307A (es) Conjugados de peptidos y oligonucleotidos.
MX2016000037A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MY188071A (en) Pyridone derivatives for the treatment of viral infections and further diseases
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen
IN2013MU03429A (es)